Alirocumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Alirocumab?
Monoclonal antibody
Source Human
Target Proprotein convertase subtilisin/kexin type 9 (PCSK9)
Clinical data
Trade names Praluent
Legal status
  • Investigational
Routes of
administration
Subcutaneous injection
Identifiers
CAS Registry Number 1245916-14-6
ATC code None
Chemical data
Formula C6472H9996N1736O2032S42
Molecular mass 146.0 kDa

Alirocumab (trade name Praluent) is an experimental human monoclonal antibody PCSK9 inhibitor designed for the treatment of hypercholesterolemia.[1] It is also known as REGN727 and SAR236553.[2] It was discovered by Regeneron Pharmaceuticals and is being co-developed with Sanofi. A main competitor in the race to worldwide health authority approval is evolocumab in development by Amgen.

Clinical trials[edit]

A phase 3 trial of statin intolerant patients called ODYSSEY ran for 65 weeks.[3] Results were presented at the 2014 European Society of Cardiology meeting.[4]

A 78-week study of alirocumab in 2341 people taking statins who were at high risk for cardiovascular events and had high LDL cholesterol levels was published in April 2015.[5]

References[edit]

  1. ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization
  2. ^ Sheridan, C (2013). "Phase 3 data for PCSK9 inhibitor wows". Nature Biotechnology 31 (12): 1057–8. doi:10.1038/nbt1213-1057. PMID 24316621.  edit
  3. ^ "Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: Design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.". Journal of Clinical Lipidology 8: 554–61. Nov–Dec 2014. doi:10.1016/j.jacl.2014.09.007. PMID 25499937. 
  4. ^ "Huge Decreases in LDL Cholesterol With Alirocumab: ODYSSEY". 
  5. ^ Robinson, Jennifer G.; Farnier, Michel; Krempf, Michel; Bergeron, Jean; Luc, Gérald; Averna, Maurizio; Stroes, Erik S.; Langslet, Gisle; Raal, Frederick J. (April 16, 2015). "Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events". New England Journal of Medicine 372 (16): 1489–1499. doi:10.1056/NEJMoa1501031. ISSN 0028-4793. PMID 25773378.